Navigation Links
ANTHELIOS 40 Sunscreen With Mexoryl(TM) SX Now Available to Consumers in the US
Date:7/1/2008

The Highest UVA & UVB Protection in a Sunscreen With Mexoryl(TM) SX

Available Nationwide

NEW YORK, July 1 /PRNewswire/ -- La Roche-Posay, the brand trusted for over 15 years worldwide to offer exceptional UVA protection(1), announces the availability of ANTHELIOS 40 Sunscreen with the highest photostable UVA and UVB protection available in a sunscreen with Mexoryl(TM) SX . ANTHELIOS 40 Sunscreen is a revolutionary new outdoor use SPF 40 sunscreen for the face and body, specifically tested for safety on those with the photosensitive skin disorder, Polymorphous Light Eruption (PMLE)(4).

Starting July 1st, ANTHELIOS 40 will be available at select physicians' offices, CVS/pharmacy (at their pharmacy counters), Duane Reade, Longs and Brooks locations with Dermo-Skincare Centers, and online at http://www.laroche-posayus.com.

Photosensitivity is a pervasive issue for people suffering from a variety of photosensitive conditions including, but not limited to, PMLE, Photoallergic Eruption (sun allergies), Phototoxicity, Solar Uticaria (sun rashes) and autoimmune disease. In fact, it is estimated that up to 17% of the US population alone experience symptoms related to PMLE as a result of UV (primarily UVA) exposure(2). These figures are likely understated as many potential patients do not seek treatment for proper diagnosis. In approximately 50% of those affected, the action spectrum is actually UVA rays(3).

La Roche-Posay ANTHELIOS 40 is the new FDA approved sunscreen for outdoor- use that has the highest UVA and UVB protection available in a sunscreen with Mexoryl(TM) SX to meet these needs. Having been tested for safety on special populations including those with photosensitive skin, such as PMLE(4), this formula provides a unique and synergistic combination of sun filters.

About ANTHELIOS 40

Innovation: A unique synergistic combination o
'/>"/>

SOURCE La Roche-Posay
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection
2. FDA Proposes New Rules for Sunscreens
3. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
4. FDA Sunscreen Labeling Decision Delayed Another Month, Leading U.S. Physician to Say, Enough Is Enough
5. Gene-Based Sunscreen Might Someday Prevent Skin Cancer
6. Choose Biodegradable Sunscreen to Save Coral Reefs
7. Renowned Doctor Says Best Way to Obtain Crucial Vitamin D Is From Sun; but Still, Dont Forget Sunscreen
8. Recent Advances Make Sunscreen More Effective and Easier to Use
9. Shining a Light on Sunscreen: Sun Protection Misconceptions Unveiled by Dr. Jeffrey Dover and CVS/pharmacy
10. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
11. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... VeloReality Inc. President Gary Bauer announced ... (RLVs) of world-famous velo courses for the company's VRide software ... popular indoor velo trainers. Two dozen additional Real Life Videos ... of November -- in time for the 2014 holiday ... in the VeloReality collection to over sixty. , The new ...
(Date:11/26/2014)... Il (PRWEB) November 27, 2014 ... excited to announce the kick-off of its annual ... encourages people to go to donate to those ... partner with local organizations to distribute the donations ... 20th, participating AlignLife locations will be accepting donations ...
(Date:11/26/2014)... Recently, Locks-Magnetic.com, a Chinese outstanding Maglocks ... magnetic locks on the Internet. It also provides a ... , As a leading company in the electronic ... customers to buy high quality locks. It can meet ... locks that are not only useful but also affordable. ...
(Date:11/26/2014)... Pharmaceutical and biotech companies require precise control ... and research activities, a task in which HVAC ... key role. Changes in temperature can promote the ... affect the quality of drugs and also support ... to address these problems and keeps the product ...
(Date:11/26/2014)... Alex Kramer HealthDay Reporter ... with rheumatoid arthritis may be more likely to achieve remission ... research. The study found that those who were heaviest ... underweight also lowered the odds of remission. "Medication for ... said Dr. Susan Goodman, the study,s lead author and a ...
Breaking Medicine News(10 mins):Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... People with bipolar,disorder and depression can find hope ... Health Care Decision Support system, available,through the Web site ... resources to support health decisions including:, -- ... depression;, -- links to online and ...
... Federal ... Regulation, ... the availability of DRA Tool(TM), a new feature of its,Sentinel RCM(TM) ... editing module that comprehensively supports the,additional reporting requirements of Section 6002 ...
... will showcase an,experimental model of a walking assist device ... with weakened leg muscles, at the,International Trade Fair on ... Disabled (BARRIER FREE 2008) which will be held at ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU095A ), Designed for people ...
... but nursing home study says risk greatest week after meds ... home patients who take antipsychotic drugs are 60 percent more ... who don,t take the drugs, a new study shows. , ... start taking the medications and gradually decreases, say Dutch researchers. ...
... surgeries has declined, so has death rate, study ... that perform fewer cardiac bypass operations don,t have more ... greater number of bypasses, a new study says. , ... hospitals that do more cardiac bypass operations have better ...
... for,Innovative Technology (CIT) today announced that CIT GAP ... Regeneration, LLC (STR), a medical,device company based in ... regeneration. CIT will invest $100,000., Joseph W. ... and counsel will help us begin developing the ...
Cached Medicine News:Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 2Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 3Health News:Sentry Data Systems Announces Deficit Reduction Act Compliance Tool 2Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 3Health News:CIT GAP Funds Invests in STR, LLC 2
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... financial results for its third quarter ended September 30, ... September 30, 2011 were $102,238 as compared to $34,446 ... nine months ended September 30, 2011, revenues were $257,609, ...
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... Senior Vice President and Chief Medical Officer. ... experience in the medical field.  He comes most recently ... and Medical Director of Global Businesses since 2005. In ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Prometheus Announces New Chief Medical Officer 2
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... This device is a qualitative ... to inspect the,overdose usage of ... a metabolite of,cocaine, in human ... of 300 ng/mL. It is ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... AcT diff2 delivers performance, ... office labs and smaller laboratories. ... that offers a small sample ... closed analysis modes, a wide ...
Medicine Products: